$WVE News

Wave Life Sciences: Q3 Earnings Snapshot

Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

Wave Life Sciences Anticipates $12M Milestone Payment From GSK In Q4

WAVE Life Sciences Q3 EPS $(0.30) Beats $(0.33) Estimate, Sales $13.158M Beat $4.317M Estimate

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026

Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026

Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views

William Blair Initiates Coverage On Wave Life Sciences with Outperform Rating

UBS Initiates Coverage On Wave Life Sciences with Buy Rating, Announces Price Target of $11

Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

Wave Life Sciences Plans For Two-Year Registrational Trial For WVE-006 To Treat Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

JP Morgan Downgrades Wave Life Sciences to Neutral

Wave Life Sciences Starts Phase 2a Clinical Study Of WVE-007 To Treat Obesity

Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

Wave Life Sciences: An Fairly Valued RNA Opportunity